TScan Therapeutics Funding: $180M Raised, Series C (2021)
TScan Therapeutics is based in Waltham. It has raised $180M in total funding. Latest round: Series C.
TScan Therapeutics funding overview
TScan Therapeutics is based in Waltham. TScan Therapeutics has raised $180M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in January 2021. The round record for TScan Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include BlackRock, RA Capital Management, Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV and 2 others. 8 distinct backers are named across the disclosed rounds.
TScan Therapeutics at a glance
Total raised
$180M
Latest round
Series C
Latest round date
January 2021
Headquarters
Waltham
Notable investors
BlackRock, RA Capital Management, Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV, Novartis Venture Fund, Pitango HealthTech
Frequently asked about TScan Therapeutics funding
How much has TScan Therapeutics raised?
TScan Therapeutics has raised $180M in total disclosed funding across the rounds on record.
Who has invested in TScan Therapeutics?
BlackRock, RA Capital Management, Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV are named among the investors backing TScan Therapeutics.
What was the latest TScan Therapeutics funding round?
The most recent disclosed round is a Series C, announced in January 2021.
Where is TScan Therapeutics based?
TScan Therapeutics is based in Waltham.
When did TScan Therapeutics last raise?
The last disclosed TScan Therapeutics round closed in January 2021 at Series C.
We update the TScan Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Waltham and their backers are listed below.
